Leap Therapeutics 미래 성장

Future 기준 확인 0/6

Leap Therapeutics은 연간 수입과 매출이 각각 6.4%와 87.8% 증가할 것으로 예상되고 EPS는 연간 17.9%만큼 증가할 것으로 예상됩니다.

주요 정보

6.4%

수익 성장률

17.9%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	87.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	15 Nov 2024

최근 미래 성장 업데이트

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18

수익 및 매출 성장 예측

NasdaqCM:LPTX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	2	-58	-67	-49	4
12/31/2025	N/A	-56	-56	-53	4
12/31/2024	N/A	-68	-64	-59	4
9/30/2024	N/A	-65	-55	-55	N/A
6/30/2024	N/A	-60	-50	-50	N/A
3/31/2024	N/A	-53	-47	-47	N/A
12/31/2023	N/A	-81	-45	-44	N/A
9/30/2023	N/A	-81	-48	-46	N/A
6/30/2023	N/A	-82	-50	-48	N/A
3/31/2023	N/A	-86	-51	-50	N/A
12/31/2022	N/A	-55	-49	-49	N/A
9/30/2022	0	-53	-47	-47	N/A
6/30/2022	1	-49	-43	-43	N/A
3/31/2022	1	-42	-38	-38	N/A
12/31/2021	2	-41	-35	-35	N/A
9/30/2021	2	-37	-30	-30	N/A
6/30/2021	2	-32	-29	-29	N/A
3/31/2021	2	-29	-31	-31	N/A
12/31/2020	2	-38	-26	-26	N/A
9/30/2020	1	-39	-26	-26	N/A
6/30/2020	1	-40	-26	-26	N/A
3/31/2020	0	-42	-24	-24	N/A
12/31/2019	N/A	-33	-27	-27	N/A
9/30/2019	N/A	-24	-28	-28	N/A
6/30/2019	N/A	-22	-29	-29	N/A
3/31/2019	N/A	-21	-27	-27	N/A
12/31/2018	N/A	-23	-26	-26	N/A
9/30/2018	N/A	-31	-25	-25	N/A
6/30/2018	N/A	-31	N/A	-20	N/A
3/31/2018	N/A	-31	N/A	-21	N/A
12/31/2017	N/A	-30	N/A	-22	N/A
9/30/2017	N/A	-29	N/A	-23	N/A
6/30/2017	N/A	-30	N/A	-28	N/A
3/31/2017	N/A	-30	N/A	-28	N/A
12/31/2016	N/A	-26	N/A	-25	N/A
9/30/2016	N/A	-23	N/A	-21	N/A
6/30/2016	N/A	-19	N/A	-15	N/A
3/31/2016	N/A	-14	N/A	-11	N/A
12/31/2015	N/A	-12	N/A	-8	N/A

애널리스트 미래 성장 예측

수입 대 저축률: LPTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: LPTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: LPTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: LPTX 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: LPTX 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: LPTX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 17:40
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Leap Therapeutics, Inc. 8 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Madhu Kumar	Baird
Joel Beatty	Baird
Swayampakula Ramakanth	H.C. Wainwright & Co.

Leap Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 10.0% to US$2.70

Price target decreased to US$3.60

Price target decreased to US$4.40

Consensus forecasts updated

Consensus revenue estimates increase by 99%

Price target increased to US$4.50

Recent updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Price target decreased by 10.0% to US$2.70

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Price target decreased to US$3.60

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

First half 2022 earnings released

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Price target decreased to US$4.40

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Consensus forecasts updated

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 99%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Leap Therapeutics: Waiting For One More Leap

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Insufficient new directors

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics: All On The Line

Price target increased to US$4.50

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

Price target decreased to US$4.00

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Consensus forecasts updated

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue and earnings miss expectations

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

New 90-day high: US$2.63

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

New 90-day high: US$2.42

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

New 90-day high: US$2.37

Analysts update estimates

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Revenue beats expectations, earnings disappoint

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day low: US$1.53

New 90-day high: US$2.19

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - US$1.76

Analysts update estimates